Posters and Presentations
- S O'Brien, J Burger, K Blum, R Furman, S Coutre, J Sharman, I Flinn, B Grant, N Heerema, A Johnson, T Navarro, E Holmgren, E Hedrick, J Byrd. The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow-up of a Phase Ib/II study [Oral Presentation] 2011 American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011.
- M Wang, P Martin, K Blum, B Kahl, L Maeda, R Advani, M Williams, S Rule, S Rodriguez, C Pang, E Hedrick, A Goy. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as a single-agent therapy in previously-treated mantle cell lymphoma (MCL): Preliminary results of a Phase II trial [Oral Presentation] 2011 American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011.
- S Herman, X Sun, J Buggy, G Aue, P Perez-Galan, A Wiestner. The Bruton Tyrosine Kinase Inhibitor, PCI-32765, Inhibits Activation and Proliferation of Human Chronic Lymphocytic Leukemia Cells in the NSG Xenograph Mouse Model of the Tissue Microenvironment [Oral Presentation] 2011 American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011.
- S Chen, J Buggy, B Chang, J Burger, N Chiorazzi. BTK Inhibitor, PCI-32765, Delays CLL Progression in a TCL1 Adoptive Transfer Model by Impairing Migration and Cell Proliferation [Oral Presentation] 2011 American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011.
- B Chang, M Francesco, P Magadala, M Huang, M Spaargaren, J Buggy, L Elias. Egress of CD19+CD5+ Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients [Oral presentation] 2011 American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011.
- S Ponader, S Balasubramanian, L Pham, J Chen, A Tamayo, M Wang, S O'Brien, W Wierda, M Keating, R Ford, J Burger. Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target [Poster] 2011 American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011.
- L Staudt, K Dunleavy, J Buggy, E Hedrick, N Lucas, S Pittaluga, S Jhavar, R Schmitz, M Williams, J Lih, E Jaffe, W Wilson. The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL [Poster # 2716] 2011 American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011.
- Y Tai, B Chang, S Kong, M Fulciniti, G Yang, Y Calle, Y Hu, J Lin, J Zhao, M Cea, A Cagnetta, M Sellitto, M Chen, Z Hunter, R Carrasco, J Buggy, L Elias, W Matsui, S Treon, P Richardson, N Munshi, K Anderson. Targeting Bruton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenstršm Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment [Oral Presentation] 2011 American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011.
- R Advani, J Sharman, S Smith, T Boyd, B Grant, K Kolibaba, R Furman, J Buggy, D Loury, E Hedrick, R Izumi, A Hamdy, and N Fowler The BTK Inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: Final results from a Phase I study [Oral Presentation] 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, June 15-18, 2011
- Susan O'Brien, MD, Jan A. Burger, MD, PhD, Steven E. Coutre, Jeff Porte Sharman, MD, Richard R. Furman, MD, Ian W. Flinn, MD, Barbara Grant MD, Donald Richards, MD, Nyla Heerema PhD, Amy J Johnson PhD, Raquel Izumi, PhD, Ahmed Hamdy, MD, Kristie A. Blum, MD, and John C. Byrd, MD The BTK Inhibitor PCI-32765 is highly active and tolerable in patients with poor-risk CLL: Interim results from a Phase Ib/II study. [Oral Presentation] 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, June 15-18, 2011
- Sabine Ponader, Kumudha Balakrishnan, Joseph Buggy, Susan O’Brien, William G. Wierda, Michael J. Keating, Varsha Gandhi and Jan A. Burger Bruton’s tyrosine kinase inhibitor PCI-32765 abrogates BCR-and nurselike cell-derived activation of CLL cells in vitro and in vivo [Oral Presentation] 2010 American Society of Hematology Annual Meeting, San Diego, CA, 10-13 December, 2010
- Jan A. Burger, MD, PhD, Susan O'Brien, MD, Nathan Fowler, MD, Ranjana Advani, MD, Jeff Porte Sharman, MD, Richard R. Furman MD, Raquel Izumi, PhD, Joseph Buggy, PhD, David Loury, PhD, Ahmed Hamdy, MD, John C. Byrd, MD, Kristie A. Blum, MD The Bruton's Tyrosine Kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL): An update on ongoing Phase I studies. [Oral Presentation] 2010 American Society of Hematology Annual Meeting, San Diego, CA, 10-13 December, 2010
- Sabine Ponader, Kumudha Balakrishnan, Joseph Buggy, Susan O’Brien, William G. Wierda, Michael J. Keating, Varsha Gandhi and Jan A. Burger Bruton’s tyrosine kinase inhibitor PCI-32765 abrogates BCR-and nurselike cell-derived activation of CLL cells in vitro and in vivo [Oral Presentation] 2010 American Society of Hematology Annual Meeting, San Diego, CA, 10-13 December, 2010
- Jan A. Burger, MD, PhD, Susan O'Brien, MD, Nathan Fowler, MD, Ranjana Advani, MD, Jeff Porte Sharman, MD, Richard R. Furman MD, Raquel Izumi, PhD, Joseph Buggy, PhD, David Loury, PhD, Ahmed Hamdy, MD, John C. Byrd, MD, Kristie A. Blum, MD The Bruton's Tyrosine Kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL): An update on ongoing Phase I studies. [Oral Presentation] 2010 American Society of Hematology Annual Meeting, San Diego, CA, 10-13 December, 2010
- Sarah E.M. Herman, PhD, Amber L. Gordon, Emilia Mahoney, MD, PhD, Samantha M. Jaglowski, MD, Kristie A. Blum, MD, Joseph Buggy, PhD, Ahmed Hamdy, MD, John C. Byrd, MD and Amy J. Johnson, PhD The Kinase Inhibitor PCI-32765 Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals [Poster Presentation] 2010 American Society of Hematology Annual Meeting, San Diego, CA, 10-13 December, 2010
- Chang B, Thiemann P, Francesco M, Huang M, Sirisawad M, Purro N, Jejurkar P, Mani C, Tonev D, Chen W, Buggy J, Loury D. PCI-45292, a Novel Btk Inhibitor with Optimized Pharmaceutical Properties, Demonstrates Potent Activities in Rodent Models of Arthritis. [Poster Presentation] American College of Rheumatology Annual Meeting, Atlanta, GA, 6-11 November, 2010
- Advani R, Sharman J, Smith S, Pollyea D, Boyd T, Grant B, Kolibaba K, Buggy J, Hamdy A, Fowler N. BTK Inhibitor PCI-32765 Monotherapy Induces Objective Responses in Patients with Relapsed Aggressive NHL: Evidence of Antitumor Activity from a Phase I Study. [Oral Presentation] American Society of Clinical Oncology 2010 Annual Meeting, Chicago, IL, 4-6 June, 2010.
- Soucek, L., Honigberg, L., Kortlever, R., Buggy, J., Swigart, L., Evan, G. Mast cell inhibition by BTK Inhibitor PCI-32765 as a potential cancer therapy. American Association for Cancer Research 2010 oral presentation.
- Pollyea, D., Smith, S., Fowler, N., et al. A Phase I Dose Escalation Study of the BTK Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma American Society of Hematology 2009 poster presentation.
- Crowley, R., Sirisawad, M., Chen, J., Merck, A., Thiemann, P., Buggy, J.J., Balasubramanian, S. The Bruton tyrosine kinase (Btk) inhibitor PCI-32765 prevents activation of pro-survival NF-kB pathways in OC-LY10 ABC DLBCL cells. AACR April 2011, Orlando, FL
Scientific Manuscripts
- Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107: 13075-13080, 2010.
- Lenz G, Staudt L. Aggressive Lymphomas. NEJM. Apr 2010; 362(15):1417-1429.
- Davis R, Ngo V, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. Jan 2010;463(7277): 88-92.
- Khan W. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res. 2001;23(2-3):147-156.
- Pan Z, Scheerens H, Li S, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem. Jan 2007;2(1):58-61.
- Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011 Mar 21 - PubMed PMID: 21422473
- Macglashan D Jr, Honigberg LA, Smith A, Buggy J, Schroeder JT. Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor. Int Immunopharmacol. 2011 Apr;11(4):475-9. Epub 2011 Jan 14.
